ArticleCancer diagnosis & prognosis
Risk Factors for Infusion Reactions Associated With Rituximab Therapy.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Although rituximab is used to treat a range of diseases, the high frequency of rituximab-associated infusion reactions (IRs) poses a clinical challenge. This study aimed to identify pre-treatment risk factors associated with rituximab-induced IRs using retrospective patient data. Patients and Methods: We retrospectively analyzed the medical records of patients treated with rituximab. Data were compared between patients with and without IRs. Results: Among the variables assessed, an elevated C-reactive protein (CRP) level prior to rituximab administration was significantly associated with IR occurrence (odds ratio=2.591; 95% confidence interval=1.160-5.791; Conclusion: Elevated pre-medication levels of CRP are a significant risk factor associated with the use of rituximab, thereby highlighting the need for close monitoring of patients receiving rituximab who present with elevated CRP levels prior to the initiation of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.